Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations - the National Israeli Study of Ovarian Cancer.
Gynecol Oncol
; 153(2): 320-325, 2019 05.
Article
em En
| MEDLINE
| ID: mdl-30872026
ABSTRACT
OBJECTIVE:
Compare 5, 10 and 15â¯year survival in invasive epithelial ovarian cancer, between patients with and without BRCA1/2 germ line mutation in a nonselective group of patients diagnosed during 1994-99.METHODS:
The analysis was based on 779 Jewish patients 229 carriers to the Ashkenazi Jewish founder mutations in BRCA1 (185delAG; 5382insC) and BRCA2 (6174delT); and 550 non-carriers. Clinical characteristics were abstracted from the patients' medical records and vital status was updated through the National Population Registry up to 11/2015. The Kaplan-Meier method, log-rank tests, and Cox-regression model were used for survival analyses.RESULTS:
By the end of the follow-up period, (range 1-20â¯years), 629 (80.7%) deaths occurred. While considerably higher survival was observed during the first 5â¯years from diagnosis among carriers compared to non-carriers (46.7% vs. 36.2%, pâ¯=â¯0.0004), the survival rates at 15â¯years were 22.3% vs. 21.8% respectively (pâ¯=â¯0.04). The age-adjusted hazard ratio for all-cause mortality of carriers versus non-carriers was 0.74 (95%CI 0.60-0.91) in the first 5â¯years. For women who survived 5 and 10â¯years, the age-adjusted hazard ratios for mortality during 5 additional years, of carriers compared to non-carriers, were 1.38 (95%CI 0.93-2.04) and 1.08 (95%CI 0.61-1.92), respectively.CONCLUSION:
The results of this study, with up to 20â¯years follow-up, support studies with shorter follow-up that suggested that the advantage in survival observed among BRCA1/2 carriers during the first 5â¯years decreases over time. Clinically, this may have implications for follow-up and therapy, especially of new agents that are particularly effective in BRCA carriers.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Ovarianas
/
Proteína BRCA1
/
Proteína BRCA2
/
Carcinoma Epitelial do Ovário
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Middle aged
País/Região como assunto:
Asia
Idioma:
En
Revista:
Gynecol Oncol
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Israel